Nnamdi Njoku Sells 3,090 Shares of Omnicell (NASDAQ:OMCL) Stock

Omnicell, Inc. (NASDAQ:OMCL) EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the transaction, the executive vice president owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. The trade was a 1.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Omnicell Stock Performance

Shares of OMCL stock opened at $44.72 on Thursday. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. The business has a 50 day moving average of $37.80 and a two-hundred day moving average of $40.68. Omnicell, Inc. has a 52 week low of $26.84 and a 52 week high of $55.00. The company has a market cap of $2.03 billion, a P/E ratio of 101.64, a PEG ratio of 1.13 and a beta of 0.96.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Tuesday, April 28th. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The company had revenue of $309.88 million during the quarter, compared to the consensus estimate of $304.02 million. During the same period in the previous year, the firm posted $0.26 earnings per share. Omnicell’s quarterly revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, analysts anticipate that Omnicell, Inc. will post 1.31 EPS for the current year.

Analyst Ratings Changes

OMCL has been the subject of several analyst reports. Benchmark reissued a “buy” rating on shares of Omnicell in a report on Friday, March 13th. Zacks Research raised shares of Omnicell from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. UBS Group set a $60.00 price objective on Omnicell and gave the stock a “buy” rating in a research report on Friday, March 13th. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Finally, Weiss Ratings upgraded Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Omnicell currently has a consensus rating of “Buy” and a consensus price target of $59.86.

Institutional Investors Weigh In On Omnicell

Institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP lifted its stake in Omnicell by 156.4% during the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after buying an additional 1,265,818 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Omnicell in the third quarter valued at $25,625,000. First Light Asset Management LLC purchased a new stake in shares of Omnicell in the first quarter valued at $16,351,000. Boston Partners purchased a new stake in shares of Omnicell in the fourth quarter valued at $20,805,000. Finally, WCM Investment Management LLC purchased a new stake in shares of Omnicell in the first quarter valued at $9,783,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.